Study Evaluating Renal Cell Carcinoma Risk Factors

Pfizer145 enrolled

Overview

This is an epidemiological, prospective, multicenter study designed to identify the pre-treatment clinical, molecular and genetic prognostic factors associated with progression free survival in patients naïve to renal cell carcinoma (RCC) treatment.

invitation to volunteer

Study Type

OBSERVATIONAL

Enrollment

145

Conditions

Carcinoma, Renal Cell

Interventions

Epidemiological study according to clinical practiceOTHER

Epidemiological study according to clinical practice.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Treatment naïve patients with proven advanced RCC will be evaluated. (Except surgery or radiotherapy) * =18 years, any gender. * Patients with advanced Renal Cell Carcinoma and treatment naïve. Exclusion Criteria: * Patients who have already initiated any kind of specific therapy for the treatment of RCC.2. * Patients with other neoplasias different from RCC (current or past).

Locations (1)

Pfizer Investigational Site

Pamplona, Navarre, Spain

Outcomes

Primary Outcomes

Progression-free survival

Time frame: 12 months

Secondary Outcomes

Response rate.

Time frame: 12 months

Overall survival.

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.